Liver Cancer Trial, Recruiting NCT06979219 Sponsor: Seoul National University Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT06979219
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a type of liver cancer called hepatocellular carcinoma, confirmed by a tissue sample or by specific imaging scan results
  • Your liver tumor(s) are 5 cm (about 2 inches) or smaller in size
  • You have 3 or fewer tumors
  • Any abnormal blood vessels inside your tumor are either absent or smaller than 3 mm
  • Your liver is functioning at a good level, based on a medical scoring system called Child-Pugh class A (confirm with trial site)
  • You are able to carry out normal daily activities, or have only minor limitations, based on a standard performance scale (confirm with trial site)
  • Your blood test results meet specific levels for white blood cells, red blood cells, liver function, kidney function, and blood clotting (confirm with trial site for exact values)
  • You are expected to live for more than 3 months
  • You have read and signed a consent form showing you understand the trial
  • If you are a woman who could become pregnant, you must not currently be pregnant

Who may not be able to join:

  • Your cancer has spread into the hepatic veins (the veins that carry blood out of the liver)
  • Imaging scans show significant abnormal activity in the portal vein or hepatic veins
  • You have abnormal blood vessels inside your tumor that are 3 mm or larger
  • You have had a procedure called a transjugular intrahepatic portosystemic shunt (a type of connection created inside the liver to manage blood pressure) (confirm with trial site)
  • You have had surgery connecting your bile ducts to your intestine, or you have a bile duct stent in place
  • You have a lung condition called centrilobular emphysema or interstitial lung disease
  • Your cancer has spread into the main portal vein (the large vein that supplies blood to the liver)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 82-10-5136-5205

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
10 June 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

complete response rate by mRECIST

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov